COMMUNIQUÉS West-GlobeNewswire

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)
29/06/2026
HORIZON is a potentially pivotal, randomized, double-blind, placebo-controlled Phase 2 study evaluating TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg as a first-line monotherapy in adults with MDD Primary [...]
BrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive Disorder
29/06/2026
Nearly half of individuals diagnosed with PTSD also meet criteria for major depressive disorder (MDD), making comorbid depression one of the most common and clinically significant complications of PTSD ~83.5% of [...]
GuideAI Health Corp. to Begin Trading on Cboe Canada Under the Symbol "GDAI"
29/06/2026
BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- GuideAI Health Corp. (" GuideAI " or the " Company ") (Cboe CA: GDAI) is pleased to report that the Company has received final approval to list its common shares (the "Shares") [...]
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
29/06/2026
Company expands executive team with strategic corporate affairs leader as it advances its differentiated obesity portfolio WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage [...]
Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength
29/06/2026
Vancouver, Canada, June 29, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]
Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes
29/06/2026
CORAL GABLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central [...]
Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET
29/06/2026
CAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, [...]
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
29/06/2026
WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer [...]
Dr. Mariusz Sapijaszko elected President of the Canadian Dermatology Association
29/06/2026
OTTAWA, Ontario, June 29, 2026 (GLOBE NEWSWIRE) -- The Canadian Dermatology Association (CDA) is pleased to announce the appointment of Dr. Mariusz Sapijaszko as CDA President, effective June 25, 2026. Dr. Mariusz [...]
George Medicines appoints Brendan Walsh as Senior Vice President of Supply Chain & Technical Operations
29/06/2026
Brendan Walsh brings more than 20 years of operational leadership to support George Medicines’ global commercial expansion of GMRx2 London, UK, Boston, MA, 29 June 2026 – George Medicines, a late-stage biopharmaceutical [...]
ITM, Helmholtz Munich and the University of Münster Announce Updated Preliminary Phase 1 Data with ITM-31 in Glioblastoma Patients
29/06/2026
Patient enrollment has been completed; all enrolled patients remain alive Data presented at the Nuclear Medicine and Neuro-Oncology (NMN) Society Annual Symposium Garching/Munich and Münster, Germany - June 29, 2026 - [...]
Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen
29/06/2026
Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer’s disease, including clinical, biomarker and safety results for Biogen’s investigational tau-targeting ASO, following topline results announced [...]
Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes
29/06/2026
NEW HOPE, Pa., June 29, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk- [...]
Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
29/06/2026
SAT-3247 has now received FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations for Duchenne muscular dystrophy (“Duchenne” or “DMD”) Fast Track is designed to expedite the development/review of new drugs [...]
Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes
29/06/2026
SAN MATEO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
29/06/2026
COPENHAGEN, Denmark, June 29, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on June 2, 2026, under which the Company will repurchase shares for an amount up to [...]
Zelluna ASA activates The Royal Marsden as second clinical site for ZIMA-101, expanding clinical execution capabilities
29/06/2026
The Royal Marsden NHS Foundation Trust activated as the second clinical site in the ZIMA-101 Phase 1 trial Patient identification, pre-screening and screening activities ongoing at first activated site Company remains [...]
Zelluna ASA: New share capital registered
29/06/2026
Oslo, Norway, 29 June 2026: Reference is made to the stock exchange announcement published by Zelluna ASA (the “ Company ”) on 18 June 2026 regarding a successfully placed private placement (the “ Private Placement ”) [...]
Aplagon Appoints Carl Lindgren as Board Chair to Guide Later Stage Clinical and Corporate Development
29/06/2026
Veteran life sciences executive brings over 30 years of strategic and commercial leadership as Aplagon advances through Phase 2 development in multiple thrombosis-inflammatory diseases HELSINKI, June 29, 2026 (GLOBE [...]

Pages